Tanimoto M, Saito H
First Department of Internal Medicine, Nagoya University School of Medicine.
Nihon Rinsho. 1992 Jun;50(6):1386-92.
Most recent progress in the treatment of leukemia and choice of therapies for obtaining "cure" from leukemia are discussed. Chemotherapy can now provide about 40% long term survival in acute myeloblastic leukemia (AML) and about 20% disease-free survival in acute lymphoblastic leukemia (ALL) of adults. Bone marrow transplantation (BMT) should be applied for the patients at risk in those leukemias (Cytogenetic abnormalities for AML and prognostic factors in ALL). In CML patients, BMT offers the only cure. Update result of interferon (IFN) therapy for CML is still a matter of controversy. Ex vivo treatment of autologous cells with IFN or drugs may be beneficial for CML patients without HLA identical donor.
讨论了白血病治疗的最新进展以及从白血病中获得“治愈”的治疗方法选择。目前,化疗可使急性髓细胞白血病(AML)患者获得约40%的长期生存率,使成人急性淋巴细胞白血病(ALL)患者获得约20%的无病生存率。对于这些白血病中有风险的患者(AML的细胞遗传学异常和ALL的预后因素)应进行骨髓移植(BMT)。在慢性粒细胞白血病(CML)患者中,BMT是唯一的治愈方法。干扰素(IFN)治疗CML的最新结果仍存在争议。对于没有 HLA 相合同胞供体的CML患者,用IFN或药物对自体细胞进行体外处理可能有益。